Can a breastfeeding mother safely receive intravenous hydrocortisone and intramuscular chlorpheniramine (Piriton)?

IV Hydrocortisone and IM Chlorpheniramine (Piriton) in Breastfeeding

Both IV hydrocortisone and IM chlorpheniramine can be safely administered to breastfeeding mothers without interrupting breastfeeding. The evidence strongly supports that corticosteroids have been used extensively during lactation with no adverse effects, and chlorpheniramine transfers to breast milk in clinically insignificant amounts.

Hydrocortisone Safety

Corticosteroids, including hydrocortisone, are compatible with breastfeeding based on extensive clinical experience. The 2020 Association of Anaesthetists guideline explicitly states that "other corticosteroids have been used extensively during breastfeeding with no evidence of any effects" when discussing dexamethasone, and this applies to all corticosteroids including hydrocortisone 1.

The FDA label for IV hydrocortisone notes that "systemically administered corticosteroids appear in human milk" but focuses primarily on chronic high-dose use concerns 2. For acute administration (such as in allergic reactions or anaphylaxis), the risk-benefit clearly favors treatment, as the amounts transferred are minimal and the maternal indication is critical.

Key Points for Hydrocortisone:

• Rapidly metabolized and cleared from maternal circulation 2
• Excretion nearly complete within 12 hours 2
• No interruption of breastfeeding required
• The infant receives far less exposure through breast milk than would be clinically significant

Chlorpheniramine (Piriton) Safety

Chlorpheniramine is compatible with breastfeeding, with a relative infant dose well below the 5% safety threshold. A 2022 systematic review found that antihistamines transfer to breast milk in very small amounts, with relative infant doses ranging from 0.3% to 4.5% - all well below the 10% threshold considered safe 3.

One study specifically examined chlorpheniramine's effect on prolactin levels in breastfeeding women and found it could be used safely 3. Additionally, a clinical trial used chlorpheniramine 10 mg IV bolus in combination with hydrocortisone for preventing adverse reactions to antivenom, demonstrating the safety of this exact combination in acute settings 4.

Key Points for Chlorpheniramine:

• Minimal transfer to breast milk
• Relative infant dose <5% (well below safety threshold)
• First-generation antihistamines may cause mild sedation in some infants, but this is uncommon at standard doses
• No need to "pump and dump" or interrupt breastfeeding

Clinical Algorithm

For acute administration (single dose or short course):

1. Administer both medications as clinically indicated - do not delay treatment due to breastfeeding concerns
2. No interruption of breastfeeding required - mother can breastfeed immediately after recovery from the acute event
3. Monitor infant for:
   • Unusual sedation (rare with chlorpheniramine at standard doses)
   • Normal feeding patterns
   • No specific monitoring needed for hydrocortisone after single/short-term use

For repeated or prolonged dosing:

1. Hydrocortisone: Continue breastfeeding; only with chronic high-dose therapy (weeks to months) should infant be monitored for signs of adrenal suppression
2. Chlorpheniramine: Prefer second-generation antihistamines (cetirizine, loratadine) for chronic use as they have better safety data, but short courses are safe

Important Caveats

Common pitfall: Healthcare providers often unnecessarily advise mothers to "pump and dump" or interrupt breastfeeding after receiving these medications. This is not evidence-based and can undermine breastfeeding success 5, 6, 7.

Timing consideration: While not required, if the mother wishes to minimize even theoretical exposure, she can breastfeed just before receiving the medications, as peak milk levels occur 30-60 minutes after IV administration. However, this is not medically necessary 8, 9.

Documentation: The AAP and Association of Anaesthetists both emphasize that most maternal medications are compatible with breastfeeding, and the default should be to continue breastfeeding unless there is specific evidence of harm 5, 1.

The evidence consistently demonstrates that acute treatment with IV hydrocortisone and IM chlorpheniramine poses no clinically significant risk to the breastfed infant and should not be withheld or delayed due to breastfeeding status.